IOVA Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- 0.00
- P/B
- 6.38
- P/S (TTM)
- 18.98
- EV/EBITDA
- -8.68
Profitability & growth
- ROE (TTM)
- -40.4%
- Operating margin
- -52.3%
- Revenue growth YoY
- 65.7%
- Dividend yield
- —
- Beta
- 0.76
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Iovance Biotherapeutics Inc
Company profileIovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 825 INDUSTRIAL ROAD, SAN CARLOS, CA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
